A comprehensive analysis of the efficacy and side effects of rasagiline (Anzilai)

Rasagiline (Rasagiline) is a monoamine oxidase B (MAO-B) inhibitor commonly used in the treatment of Parkinson's disease and has important clinical therapeutic value. It inhibits the decomposition of dopamine in the brain and prolongs the action time of dopamine in the synaptic gap, thereby improving the patient's motor symptoms, such as tremor, stiffness, bradykinesia, etc. Compared with traditional levodopa, rasagiline is more likely to be used as a single agent in early treatment or in combination with levodopa after disease progression to delay the occurrence of motor complications. Studies have shown that rasagiline has a positive effect in improving quality of life, delaying the deterioration of motor symptoms, and maintaining neuroprotection. Therefore, it is recommended as one of the first-line drugs by the international Parkinson's disease treatment guidelines.

In terms of efficacy, rasagiline has several outstanding advantages. First of all, as a highly selective MAO-B inhibitor, it can effectively reduce the frequency and dosage of levodopa, and reduce motor complications caused by long-term use of large doses of levodopa, such as dyskinesia and movement fluctuations. Secondly, the monotherapy effect of rasagiline is relatively stable and can delay the progression of the disease, which is especially suitable for patients with early-stage Parkinson's disease. Third, some studies suggest that rasagiline may have neuroprotective effects and delay neuronal damage through antioxidant, anti-apoptotic and other mechanisms. Although this is still being further studied and verified, its potential value has attracted great attention from the medical community. In addition, rasagiline is easy to take, usually once a day, has high patient compliance, and is suitable for long-term maintenance treatment.

However, while rasagiline exerts its therapeutic effect, it may also cause certain adverse reactions and side effects. Common side effects include headache, joint pain, fatigue, nausea, dry mouth, and insomnia. These symptoms are usually mild and gradually reduce as the medication is prolonged. It is important to note that rasagiline may cause hypotension or orthostatic hypotension, resulting in dizziness or an increased risk of falls. In addition, patients are more likely to experience movement-related adverse reactions, such as dyskinesia, when combined with levodopa therapy. Rarely, rasagiline may have serious interactions with certain drugs. For example, when combined with selective 5-serotonin reuptake inhibitors (SSRIs), tricyclic antidepressants, triptans, etc., rasagiline may induce serotonin syndrome, manifested by severe symptoms such as high fever, muscle stiffness, and mental status changes. Therefore, clinicians need to carefully evaluate drug interactions when prescribing.

Overall, rasagiline, as an important drug in the treatment of Parkinson's disease, has clear value in improving motor symptoms, delaying disease progression, and improving patients' quality of life. Its once-daily dosing regimen and high selectivity make it relatively superior in side effect control. However, patients need to closely monitor changes in blood pressure, mental status and motor symptoms during medication, strictly follow medical instructions, and avoid using contraindicated drugs at the same time. As more clinical studies are conducted in the future, the neuroprotective effect and long-term efficacy of rasagiline are expected to be further confirmed, which will bring more hope to patients with Parkinson's disease. For patients, correctly understanding its efficacy and potential side effects and actively cooperating with doctors for individualized treatment are the keys to safe and effective drug efficacy.

Reference link:https://www.drugs.com